ZA202309517B - Solid forms of a modulator of hemoglobin - Google Patents
Solid forms of a modulator of hemoglobinInfo
- Publication number
- ZA202309517B ZA202309517B ZA2023/09517A ZA202309517A ZA202309517B ZA 202309517 B ZA202309517 B ZA 202309517B ZA 2023/09517 A ZA2023/09517 A ZA 2023/09517A ZA 202309517 A ZA202309517 A ZA 202309517A ZA 202309517 B ZA202309517 B ZA 202309517B
- Authority
- ZA
- South Africa
- Prior art keywords
- hemoglobin
- modulator
- solid forms
- forms
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188833P | 2021-05-14 | 2021-05-14 | |
| PCT/US2022/029289 WO2022241278A1 (en) | 2021-05-14 | 2022-05-13 | Solid forms of a modulator of hemoglobin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202309517B true ZA202309517B (en) | 2024-06-26 |
Family
ID=82020064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/09517A ZA202309517B (en) | 2021-05-14 | 2023-10-11 | Solid forms of a modulator of hemoglobin |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11851424B2 (https=) |
| EP (1) | EP4337659A1 (https=) |
| JP (1) | JP2024520897A (https=) |
| KR (1) | KR20240008356A (https=) |
| CN (1) | CN117337285A (https=) |
| AR (1) | AR126649A1 (https=) |
| AU (1) | AU2022273787B2 (https=) |
| BR (1) | BR112023021606A2 (https=) |
| CA (1) | CA3219786A1 (https=) |
| MX (1) | MX2023012156A (https=) |
| TW (1) | TW202311254A (https=) |
| WO (1) | WO2022241278A1 (https=) |
| ZA (1) | ZA202309517B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250041312A1 (en) * | 2021-12-10 | 2025-02-06 | Global Blood Therapeutics, Inc. | Methods of administering a modulator of hemoglobin |
| TW202515579A (zh) * | 2023-06-13 | 2025-04-16 | 美商全球血液治療公司 | 投予血紅素的調節劑之方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4432987A (en) * | 1982-04-23 | 1984-02-21 | Pfizer Inc. | Crystalline benzenesulfonate salts of sultamicillin |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| SG10201802911RA (en) * | 2013-03-15 | 2018-05-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| HRP20220295T1 (hr) | 2018-11-19 | 2022-05-13 | Global Blood Therapeutics, Inc. | Spojevi 2-formil-3-hidroksifeniloksimetila koji mogu modulirati hemoglobin |
| WO2022241286A1 (en) * | 2021-05-14 | 2022-11-17 | Global Blood Therapeutics, Inc. | Methods of making a modulator of hemoglobin |
-
2022
- 2022-05-13 CA CA3219786A patent/CA3219786A1/en active Pending
- 2022-05-13 CN CN202280035091.5A patent/CN117337285A/zh active Pending
- 2022-05-13 EP EP22729906.2A patent/EP4337659A1/en active Pending
- 2022-05-13 JP JP2023569774A patent/JP2024520897A/ja active Pending
- 2022-05-13 KR KR1020237043235A patent/KR20240008356A/ko active Pending
- 2022-05-13 MX MX2023012156A patent/MX2023012156A/es unknown
- 2022-05-13 AU AU2022273787A patent/AU2022273787B2/en active Active
- 2022-05-13 WO PCT/US2022/029289 patent/WO2022241278A1/en not_active Ceased
- 2022-05-13 AR ARP220101301A patent/AR126649A1/es not_active Application Discontinuation
- 2022-05-13 TW TW111118076A patent/TW202311254A/zh unknown
- 2022-05-13 BR BR112023021606A patent/BR112023021606A2/pt unknown
- 2022-05-13 US US17/744,537 patent/US11851424B2/en active Active
-
2023
- 2023-10-11 ZA ZA2023/09517A patent/ZA202309517B/en unknown
- 2023-11-01 US US18/499,491 patent/US12473277B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023012156A (es) | 2023-10-26 |
| BR112023021606A2 (pt) | 2023-12-19 |
| CN117337285A (zh) | 2024-01-02 |
| EP4337659A1 (en) | 2024-03-20 |
| US20220363674A1 (en) | 2022-11-17 |
| US11851424B2 (en) | 2023-12-26 |
| AR126649A1 (es) | 2023-11-01 |
| US12473277B2 (en) | 2025-11-18 |
| AU2022273787B2 (en) | 2025-04-03 |
| JP2024520897A (ja) | 2024-05-27 |
| AU2022273787A1 (en) | 2023-10-26 |
| TW202311254A (zh) | 2023-03-16 |
| US20240076290A1 (en) | 2024-03-07 |
| CA3219786A1 (en) | 2022-11-17 |
| KR20240008356A (ko) | 2024-01-18 |
| WO2022241278A1 (en) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202309517B (en) | Solid forms of a modulator of hemoglobin | |
| HUE069590T2 (hu) | PCSK9-gátló 6'-[[(1s,3s)-3-[[5-(difluormetoxi)-2-pirimidinil]amino]ciklopentil]amino][1(2h ),3'-bipiridin]-2-on és alkalmazására szolgáló eljárások | |
| WO2020053365A3 (en) | Pesticidally active azole-amide compounds | |
| ZA202107668B (en) | Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione | |
| SA515360022B1 (ar) | أملاح وصور صلبة من المركب (s) ــ 3 ــ(4 ــ((4ــ(مورفولينو ميثيل)بنزيل)أوكسي)-1-أوكسو أيزو إندولين-2-يل)ببريدين-2 ،6-دايون، وتركيبات تشتمل عليها، وطرق استخدامها | |
| EP4467143A3 (en) | 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile as antiproliferative compound | |
| UA85686C2 (ru) | Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}- 1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его применение как лекарственного средства, способ его получения | |
| IL278854A (en) | Treatment of multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazine-1 -yl-3-fluorobenzonitrile | |
| TW200606144A (en) | Crystal of 1,2-dihydropyridine compound | |
| UA88767C2 (uk) | Ppar активні сполуки | |
| PL338129A1 (en) | Crystalline form of a derivative of n-phenyl-2-dipyrimidin amine, methods of obtaining same and apllication thereof | |
| DK2044043T4 (da) | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazinhydrobromid som en forbindelse med kombineret serotoningenoptag, 5-ht3 og 5-ht1a-aktivitet til behandling af kognitiv svækkelse | |
| GEP20084341B (en) | Aminoheteroaryl compounds as protein kinase inhibitors | |
| CO6400224A2 (es) | Purificación de 1-[2-(2-4-dimetilfenilsulfanil)fenil]piperazina | |
| EP3735243A4 (en) | ISOTOPOLOGISTS OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE | |
| WO2021079196A3 (en) | Mettl3 modulators | |
| IL292265A (en) | Methods for treating chronic lymphocytic leukemia using 2-(2,6 deoxypyridin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl(benzyl(amino(amino(isoindoline-1. 3- discussion | |
| GB2637104B (en) | Method for cryopreserving engineered Tregs | |
| WO2008011483A3 (en) | Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds | |
| MX2023001805A (es) | Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida. | |
| PH12021550432A1 (en) | Kits and methods for treating cancers | |
| MX2024004871A (es) | Compuesto que contiene piridilo. | |
| AU2020326552A8 (en) | Pyrimidine-5-carboxamide compound | |
| MXPA05013034A (es) | N-alquinil-2-heteroariloxialquilamidas para uso como fungicidas. | |
| WO2023076271A8 (en) | Engineered tissue constructs and methods of making the same |